Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling.

Molina A, Belldegrun A.

J Urol. 2011 Mar;185(3):787-94. doi: 10.1016/j.juro.2010.10.042. Review. Erratum in: J Urol. 2011 Aug;186(2):762.

PMID:
21239012
2.

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.

Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Bañuelos CA, Williams DE, McEwan IJ, Wang Y, Sadar MD.

Cancer Cell. 2010 Jun 15;17(6):535-46. doi: 10.1016/j.ccr.2010.04.027.

3.

Inhibition of glycogen synthase kinase-3beta promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines.

Schütz SV, Cronauer MV, Rinnab L.

J Cell Biochem. 2010 Apr 15;109(6):1192-200. doi: 10.1002/jcb.22500.

PMID:
20127713
4.

Cytoplasmic accumulation of glycogen synthase kinase-3beta is associated with aggressive clinicopathological features in human prostate cancer.

Li R, Erdamar S, Dai H, Sayeeduddin M, Frolov A, Wheeler TM, Ayala GE.

Anticancer Res. 2009 Jun;29(6):2077-81.

5.
6.

Cytoplasmic localization of the androgen receptor is independent of calreticulin.

Nguyen MM, Dincer Z, Wade JR, Alur M, Michalak M, Defranco DB, Wang Z.

Mol Cell Endocrinol. 2009 Apr 10;302(1):65-72. doi: 10.1016/j.mce.2008.12.010.

7.

In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.

Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS.

Clin Cancer Res. 2009 Jan 1;15(1):39-47. doi: 10.1158/1078-0432.CCR-08-1726.

8.

Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells.

Sadar MD, Williams DE, Mawji NR, Patrick BO, Wikanta T, Chasanah E, Irianto HE, Soest RV, Andersen RJ.

Org Lett. 2008 Nov 6;10(21):4947-50. doi: 10.1021/ol802021w.

PMID:
18834139
9.

A cellular conformation-based screen for androgen receptor inhibitors.

Jones JO, Diamond MI.

ACS Chem Biol. 2008 Jul 18;3(7):412-8. doi: 10.1021/cb800054w.

PMID:
18582038
10.

Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful?

Rinnab L, Schütz SV, Diesch J, Schmid E, Küfer R, Hautmann RE, Spindler KD, Cronauer MV.

Neoplasia. 2008 Jun;10(6):624-34.

11.

Activation of the DNA-dependent protein kinase stimulates nuclear export of the androgen receptor in vitro.

Shank LC, Kelley JB, Gioeli D, Yang CS, Spencer A, Allison LA, Paschal BM.

J Biol Chem. 2008 Apr 18;283(16):10568-80. doi: 10.1074/jbc.M800810200.

12.

Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway.

Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, Ma AH, Wang LY, Fitzgerald LD, Wu Z, Gandour-Edwards R, deVere White RW, Kung HJ.

Oncogene. 2008 Jan 17;27(4):499-505.

PMID:
17653089
14.

A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation.

Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V.

Mol Cell. 2006 Nov 17;24(4):627-33.

15.

Androgen receptor coregulators and their involvement in the development and progression of prostate cancer.

Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM.

Int J Cancer. 2007 Feb 15;120(4):719-33. Review.

16.

Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression.

Cronauer MV, Ince Y, Engers R, Rinnab L, Weidemann W, Suschek CV, Burchardt M, Kleinert H, Wiedenmann J, Sies H, Ackermann R, Kröncke KD.

Oncogene. 2007 Mar 22;26(13):1875-84.

PMID:
16983333
18.

Photoconvertible fluorescent protein EosFP: biophysical properties and cell biology applications.

Nienhaus GU, Nienhaus K, Hölzle A, Ivanchenko S, Renzi F, Oswald F, Wolff M, Schmitt F, Röcker C, Vallone B, Weidemann W, Heilker R, Nar H, Wiedenmann J.

Photochem Photobiol. 2006 Mar-Apr;82(2):351-8. Review.

PMID:
16613485
19.

The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions.

Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma AA, Miner JN, Diamond MI.

Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9802-7.

20.

Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth.

Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM.

Oncogene. 2004 Oct 14;23(47):7882-92.

PMID:
15361837
Items per page

Supplemental Content

Support Center